Urbi Berzenn, Corbett Joel, Hughes Ian, Owusu Maame Amma, Thorning Sarah, Broadley Simon A, Sabet Arman, Heshmat Saman
Office for Research Governance and Development, Gold Coast Hospital and Health Service, QLD, Australia.
School of Medicine, Griffith University, QLD, Australia.
J Parkinsons Dis. 2022;12(2):495-508. doi: 10.3233/JPD-212923.
The legalization of cannabis in many countries has allowed many Parkinson's disease (PD) patients to turn to cannabis as a treatment. As such there is a growing interest from the PD community to be properly guided by evidence regarding potential treatment benefits of cannabis. This systematic review and meta-analysis aims to compile the best available evidence to help guide patients and their family, clinicians and researchers make informed decisions. A systematic search of the literature was conducted in June 2021. Five randomized controlled studies and eighteen non-randomized studies investigated cannabis treatment in PD patients. No compelling evidence was found to recommend the use of cannabis in PD patients. However, a potential benefit was identified with respect to alleviation of PD related tremor, anxiety, pain, improvement of sleep quality and quality of life. Given the relative paucity of well-designed randomized studies, there is an identified need for further investigation, particularly in these areas.
许多国家大麻合法化使得许多帕金森病（PD）患者将大麻作为一种治疗手段。因此，帕金森病群体越来越希望能得到关于大麻潜在治疗益处的证据的恰当指导。本系统评价和荟萃分析旨在汇总现有最佳证据，以帮助指导患者及其家属、临床医生和研究人员做出明智的决策。2021年6月对文献进行了系统检索。五项随机对照研究和十八项非随机研究对帕金森病患者的大麻治疗进行了调查。未发现有令人信服的证据推荐帕金森病患者使用大麻。然而，在缓解帕金森病相关震颤、焦虑、疼痛、改善睡眠质量和生活质量方面发现了潜在益处。鉴于精心设计的随机研究相对较少，明确需要进一步开展研究，尤其是在这些领域。
